Small‐molecule inhibitors targeting p66Shc's SH2 or PTB domains have shown promise in disrupting its interactions with RTKs, inhibiting PI3K/Akt and MAPK/ERK signalling in NSCLC and BC models [20]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.